Targeted Molecular Diagnostics (TMD) has formulated a proprietary solution of broad-spectrum phosphatase inhibitors in the PhosphoGuard kit which has been used in several Phase II and III oncology clinical trials for targeted therapies such as Tykerb. PhosphoGuard is available in a 10-test research use format or as a comprehensive single use kit designed for use in clinical trials.
Phosphorylated proteins are useful markers that may be essential in predicting patient response or resistance to targeted cancer therapies.